List view / Grid view
Drug discovery research is funded primarily by government and by philanthropic groups. Later development is funded mainly by pharmaceutical companies.
Kidney cancer rates have increased by 40% over the last 10 years in the UK, and the rise is expected to continue. An estimated 20,000 kidney cancer cases have been caused by obesity over the last decade in England, according to new figures from Cancer Research UK.
The market of preventive digital health services is estimated to be worth several billion euros in the near future.
We caught up with Dr Josephine Bunch to find out how NPL are using the Cancer Research Grand Challenge funding & novel imaging techniques to map cancer tumours...
Over 10 million units of platelets are transfused worldwide each year in one of the most common procedures in clinical medicine. However, platelets derived from human donors can transmit infections and trigger serious immune reactions that eventually render the therapy ineffective (a condition known as alloimmune refractoriness). In addition, since…
Scientists will develop and test promising new molecules for targeting RAS, one of the most common driving mutations in aggressive, hard to treat cancers including pancreatic and lung cancer.
Over 90 million blood transfusions are carried out worldwide each year and alternative sources to donor-derived blood are being sought to meet rising demand. In addition there is a need to secure a safer supply of blood products, chiefly in developing countries where there is a relatively higher risk of…
Biochemist and physician Professor Ivan Dikic and microbiologist Professor Volker Müller are very honoured that their pioneering research projects have been selected for this substantial financial support.
Polyphor Ltd, a clinical stage, privately held Swiss specialty pharma company focused on the development of macrocycle drugs addressing antibiotic resistance and respiratory diseases, has completed a CHF 40 million private placement. Exisiting Polyphor investors contributed to 98% of the financing.
Meningococcal infections are the most common cause of bacterial meningitis in the United Kingdom, a life-threatening disease that poses a continuing threat worldwide. With growing fears around the increase of antibiotic-resistant bacteria, understanding why certain strains don't respond to vaccines could prove vital in helping reduce the number of global…
A research team from Instituto Gulbenkian de Ciencia (IGC, Portugal), developed a new genetic technique that allows the elimination of specific neurons of the peripheral nervous system without affecting the brain.
Karolinska development's portfolio company Aprea Therapeutics, a privately held, clinical stage biopharmaceutical company developing novel anticancer therapies targeting the tumour suppressor protein p53, announced a collaboration with Memorial Sloan Kettering Cancer Center to study the effects of reactivation of tumour suppressor protein p53 by APR-246.
The development of new treatments for pancreatic cancer is set to be transformed by a network of clinical trials, aiming to find the right trial for the right patient, after a £10 million investment from Cancer Research UK.
Sound Pharmaceuticals has been awarded up to $1.6M from Cystic Fibrosis Foundation Therapeutics (CFFT), the non-profit drug discovery and development affiliate of the Cystic Fibrosis Foundation.
Sanofi and Lonza have entered into a strategic partnership to build and operate a large-scale mammalian cell culture facility for monoclonal antibody production in Visp, Switzerland.
Our blood stem cells generate around a thousand billion new blood cells every day. But the blood stem cells’ capacity to produce blood changes as we age. This leads to older people being more susceptible to anaemia, lowered immunity and a greater risk of developing certain kinds of blood cancer.
